Kornimate/medical-research-clean huggingface dataset:
patients perspectives on discontinuation of their fertility treatment due to the covid-19 pandemic

Conditions: Coronavirus; COVID; ART; Fertility Issues

Summary: the covid-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. from march 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. a view days later, on march 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. as recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. there is little information available for women aiming for pregnancy or embarking on assisted conception. given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. a questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the covid-19 pandemic. the questionnaire contains the following sections: * demographic variables; * questions regarding the fertility history of the respondent; * questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during covid-19 on their life, psychological wellbeing and relationship; * questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; * questions regarding the satisfaction of measures taken by their fertility center regarding the covid-19 pandemic; * questions regarding expectations of further treatments, with focus on safety issues related to the covid-19 pandemic. eligible patients will be selected electronically from our database and digital agenda. after selection, patients will be contacted via email to participate. two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.


Eligibility criteria:
inclusion criteria: * patients that did not start a fertility treatment yet ("intake group") or; * patients for which a treatment plan was made, but treatment was postponed ("before treatment") or; * patients who were undergoing a non-inf treatment cycle (ovulation-induction (oi), intra-uterine insemination (iui)) and whose cycle was cancelled after starting the treatment cycle ("non-ivf treatment group") or; * patients who were undergoing a cryo cycle and whose cycle was cancelled after starting the treatment cycle ("cryo treatment group") or; * patients who were undergoing an ivf treatment cycle and for whom fresh embryo transfer was cancelled (freeze-all group). exclusion criteria: * language other than dutch
observational study of elizaria® in ahus patients

Conditions: Atypical Hemolytic Uremic Syndrome; aHUS

Summary: it is a multicenter observational non-comparative study of the efficacy and safety of long-term pathogenetic elizaria® therapy in patients with atypical hemolytic uremic syndrome

after screening, patients meeting all of the inclusion / non-inclusion criteria and vaccinated against meningococcal infections were treated by elizaria®. the study is planned to include at least 50 patients receiving elizaria® for the ahus treatment. the study will consist of a screening period of up to 4 weeks, including, if necessary, immunization with meningococcal vaccine, a treatment period of 52 weeks. medication will be prescribed in accordance with routine medical practice. accordingly to minimize the risks and subjectivity of assessments the methods adopted in the routine practice of treating patients with ahus will be used. investigators enroll patients with ahus diagnosis who have indications for pathogenetic therapy and who are receiving elizaria® under the government program. patients will receive medication in accordance with the established requirements of national standards and protocols for the treatment of patients with ahus. the registration of the amount of the drug used will be carried out on the basis of information in the patient diaries, as well as primary documentation.

Eligibility criteria:
inclusion criteria 1. written informed consent to study participation. 2. male and female patients aged 2 months and older with documented atypical hemolytic uremic syndrome (ahus)diagnosis. 3. by the time of inclusion in the study, elizaria® should be prescribed as a pathogenetic therapy for ahus; exclusion criteria 1. intolerance to eculizumab, or other components of the drug.

Keywords: atypical hemolytic uremic syndrome azotemia hemolytic-uremic syndrome hemolysis syndrome disease pathologic processes uremia kidney diseases urologic diseases anemia, hemolytic anemia hematologic diseases thrombotic microangiopathies thrombocytopenia blood platelet disorders
second-generation antipsychotic treatment indication effectiveness and tolerability in youth (satiety) study

Conditions: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychotic Disorder, Not Otherwise Specified; Prodromal Schizophrenia; Mood Disorder; Bipolar Disorder; Major Depressive Disorder; Depressive Disorder, Not Otherwise Specified; Mood Disorder, Not Otherwise Specified; Autism Spectrum Disorder

Summary: the purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents. the study's primary aim is to identify genetic risk factors for weight gain and metabolic abnormalities.

participants will be evaluated for biological and genetic risk factors for nutritional and metabolic adverse effects associated with sgaps (second generation antipsychotics) during 4 visits over 12 weeks. participants will also be evaluated at month 6, 9, and 12. this study does not involve treatment for participants. treatment of subjects enrolled in this study will be determined by their clinician and will remain unaffected by participation in this observational minimal risk study. all participants were prescribed risperidone (risperdal) for the duration of study participation and doses ranged from 0.25mg to 6mg daily for 52 weeks.

Eligibility criteria:
inclusion criteria: 1. patients between the ages of 3 and 19 (at the time of consent) 2. clinical diagnosis of psychotic disorders (i.e., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified and prodromal schizophrenia (as defined by the scale of prodromal symptoms (sops: miller 1996)), mood disorder (i.e., bipolar disorder, major depressive disorder, depressive disorder not otherwise specified, mood disorder not otherwise specified) or an autism spectrum disorder. 3. subjects who are considered for treatment with second generation antipsychotics (sgaps) by a physician who has evaluated him/her 4. subjects who are either a) antipsychotic naïve and have started an sga within the past 2 weeks , b) have started a new antipsychotic within the past 2 weeks (specifically within 2 weeks of their first blood draw), or exclusion criteria: 1. individuals younger than 3 years or older than 19 years and 11 months (at the time of consent) 2. personal history of or comorbid eating disorders 3. active hyper-/hypothyroidism 4. pregnancy 5. severe medical disorder (i.e., aids, cancer, sepsis, etc.).

Keywords: second generation antipsychotics schizophrenia schizoaffective schizophreniform psychosis nos mood disorders weight autism
a study to observe treatment patterns and outcomes in participants in saudi arabia with human epidermal growth factor receptor 2 (her2-positive) unresectable locally advanced or metastatic breast cancer (la/mbc)

Conditions: Metastatic Breast Cancer

Summary: this is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable la/mbc made up to 6 months prior to registry enrollment. these participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.


Eligibility criteria:
inclusion criteria: * initially diagnosed with her2-positive unresectable la/mbc no more than 6 months prior to enrollment * able to comply with the study protocol exclusion criteria: none
photo-activated disinfection versus triple-antibiotic paste for management of necrotic young permanent anterior teeth

Conditions: Pulp Necrosis

Summary: this study aims to compare regenerative endodontics for necrotic young permanent anterior teeth using oral photo-activated disinfection versus triple antibiotic paste in terms of: 1. clinical success in terms of absence of any complication such as spontaneous pain, sinus or swelling. 2. radiographic success in terms of healing of periapical radiolucency or increase root thickness, length or apical closure.

disinfection of the root canal system is thought to be critical to the success of regenerative endodontic procedures (reps) as infection prevents regeneration, repair and stem cell activity . a suitable material for using as intra-canal medicament seems to be antibiotic. triple antibiotic paste (tap) containing metronidazole, ciprofloxacin and minocycline has been reported to be a successful regimen in controlling the root canal pathogen and in managing necrotic young permanent tooth . recently, new disinfection methods have been developed to overcome the limitations of conventional disinfecting protocols that they may neither reduce the number of bacteria to a satisfactory level nor minimize the toxicity to periapical stem/progenitors . other concerns regarding the use of tap are tooth discoloration after treatment and bacterial resistance. photo-activated oral disinfection is a novel disinfection method which present a great solution for the problem associated with triple antibiotic paste

Eligibility criteria:
inclusion criteria: * healthy children with no physical, mental or systemic conditions. * developmental age of the child is the most important factor so periapical x- ray will be taken first to assure apex immaturity. * no sex predilection. * restorable necrotic young permanent anterior teeth exclusion criteria: * root fracture. * internal or external root resorption. * parents or guardians refuse to participate in the study.
correlation between postoperative pain and apical extrusion of different irrigation activation techniques

Conditions: Pulpitis - Irreversible

Summary: the aim of this clinical trial is : to evaluate effect of different techniques of irrigant activation: 1. laser activation 2. sonic activation 3. ultrasonic activation 4. passive needle irrigation on: 1. postoperative pain in vital teeth (randomized controlled trial) 2. amount of apical extrusion (in vitro study) participants will describe their preoperative pain and postoperative pain level at fixed time interval research will compare postoperative pain accompanied with different irrigant activation techniques and correlate it to amount of debris extrusion


Eligibility criteria:
inclusion criteria: * age group 18-50 years * males and females * lower molars with symptomatic irreversible pulpitis without apical periodontitis exclusion criteria: * patients with uncontrolled health conditions * immunocompromised patients * teeth with periodontal diseases * teeth with calcified canals * pregnant patients

Keywords: irrigant , ultrasonic, laser , sonic
"impact of a nursing intervention in the management of oncological patients with lung cancer under treatment with immunotherapy"

Conditions: Lung Cancer

Summary: introduction. lung cancer is very common worldwide with 2.09 million cases in 2018. immunotherapy has become a mainstay in cancer treatment. there is insuficient knowledge about the impact of altered needs, as well as the interventions developed by the nurse that are aimed at cancer patients in immunotherapy treatment. objectives. describe the needs of non-microcytic lung cancer patients in immunotherapy. and, evaluate the effectiveness of a nurse intervention program aimed at these patients in decreasing comorbidities, increasing satisfaction, early detection of symptoms and management of toxicities, quality of life and monitoring of anthropometric indicators. methodology. phase 1: descriptive, cross-cutting and prospective study. phase 2: quasi-experimental pre-post study. the sample is patients of the hospital de la santa creu i sant pau, with non-microcytic lung cancer in treatment with checkpoints inhibitor antibodies. the dependent variables: sociodemographic variables, clinical variables, satisfaction, quality of life, nutritional status, psychological impact, toxicities, number of unscheduled visits and health costs. independent variable: nurse intervention program. implications for practice: knowing the needs of patients in immunotherapy treatment will allow the development of a nurse care program to meet these needs and evaluate the program.


Eligibility criteria:
inclusion criteria: * patient of legal age (\> or equal to 18 years), either male or female. * patient diagnosed with lung cancer regardless of subtype and / or stage. except for small cell lung cancer, since this subtype of lung cancer is very different from the others and requires its own study. * patient receiving immunotherapy regardless of the treatment line. * patient who receives immunotherapy regardless of whether it is monotherapy or combination of chemotherapy. * patient who is able to consent to participate in the study. * patient who can read, understand and can communicate verbally. exclusion criteria: * patient diagnosed with lung cancer synchronously with another neoplasm. * patients with speech disorders. * patients who do not understand or speak spanish, catalan or english.

Keywords: immunotherapy lung cancer nurse intervention program
deep rtms modulating insula synaptic density and smoking behavior in schizophrenia

Conditions: Schizophrenia; Smoking Cessation; Tobacco Use

Summary: purpose of the study: evaluate the effect of deep repetitive transcranial magnetic stimulation (deep rtms; hereafter abbreviated as "dtms") on synaptic density measured with positron emission tomography (pet) and the radiotracer \[11c\]ucb-j. the investigators also seek to link plasticity changes in the regions targeted by the electric field (especially, the insula) to changes in the functioning of insula circuits and behavioral cigarette usage in patients with schizophrenia (scz). importance of the study: this is the first study designed to directly evaluate the mechanism of action (moa) of dtms for smoking disruption in patients with scz. patients with scz are a vulnerable population in high, immediate need of new smoking therapeutics for reducing premature morbidity and mortality.


Eligibility criteria:
inclusion criteria: 1. ages 18-60 2. dsm-5 criteria for schizophreniform, schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified (nos). 3. dsm-5 diagnosis of nicotine use disorder with current daily smoking, and a desire to cut down or quit. 4. negative urine toxicology (other than cannabis) maintained throughout study participation 5. fluent english speaker 6. capacity for informed consent exclusion criteria: 1. clinically significant psychopathology other than schizophrenia, schizophreniform, schizoaffective disorder, or psychotic disorder nos 2. current or past substance use disorder, except tud 3. current use of smoking cessation medications/products 4. change in schizophrenia medication within 4 weeks 5. hospitalization in the last 3 months 6. history of suicidal or homicidal tendencies 7. history of epilepsy, stroke, cerebral aneurysm, significant head injury resulting in \>10 min loss of consciousness, movement disorder, clinically significant electrolyte abnormalities, or use of clozapine (seizure risks) 8. pregnancy or lactation (females) 9. lack of effective birth control (females) 10. contraindications to mri or pet 11. clinical global impressions (cgi) rating of 6 (severely ill) or 7 (extremely ill) 12. prisoners 13. contraindications to dtms\* * the fda website currently states that the brainsway device used in this study is contraindicated for patients who have "metallic objects or implanted stimulator devices in or near the head, including cochlear implants, deep brain stimulators, vagus nerve stimulators, other implanted electrodes or stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes." the investigators will monitor the fda guidelines and implement any changes to the inclusion/exclusion criteria based on their most updated recommendations.

Keywords: pet ucb-j fmri schizophrenia smoking cessation tobacco use
haemorrhages and thromboembolic venous disease of the postpartum

Conditions: Postpartum Hemorrhage; Venous Thromboembolism

Summary: the aim of this study is to evaluate the frequencey and the determinants of postpartum major complications (hemorrhage and thrombosis) up to 3 months after delivery in the maternity hospitals of finistère (bretagne - france)

this is an analytical observational prospective multicenter cohort study , conducted on all the maternity hospitals in finistère (bretagne - france), with a biological collection. this protocol allows to study all women at risk of pph (postpartum hemorrhage) and postpartum venous thromboembolic disease, including maternity level 1-3 without case selection. the prospective nature of the study should provide a more detailed analysis of exposures in this particular population of women (risk factors related to the field, childbirth, the postpartum events ...). the events of interest were pph and venous thromboembolic disease.

Eligibility criteria:
inclusion criteria: * any woman giving birth and supported in one of gynaecology obstetrics services of a maternity finistere. * women ≥ 16 at the time of the collection of non-opposition. * for minor patients: understanding the patient and at least one parent. * all births ≥ 15 weeks gestation. exclusion criteria: * home birth * expressed opposition to participation in this study. * childbirth under x. * parent (s) uninformed of the pregnancy of their child.

Keywords: postpartum hemorrhage venous thromboembolism pregnancy
plasma therapy of covid-19 in severely ill patients

Conditions: SARS-CoV-2 Infection

Summary: this randomized blinded multi-center phase 2 trial will assess the efficacy and safety of anti-sars-cov-2 convalescent plasma among adults with severe covid-19. adults ≥18 years of age may participate. a total of 219 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer anti-sars-cov-2 plasma or non-convalescent fresh frozen plasma (control plasma).

there are few effective therapies for coronavirus disease 2019 (covid-19) associated with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection. exposure to viruses results in an adaptive immune response that commonly include antibodies with neutralization activity. plasma from subjects who have recovered from viral infections has been used to both prevent or treat disease. notable examples of the successful use of convalescent plasma (cp) include influenza, measles, argentine hemorrhagic fever, middle east respiratory syndrome (mers), ebola and severe acute respiratory syndrome (sars-cov). small clinical trials and observational studies of cp therapy in patients with covid-19 have suggested a possible clinical benefit.

Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent prior to performing study procedures or have a legally authorized representative available to do so. * age ≥18 years * evidence of sars-cov-2 infection by pcr test of naso-/oro-pharyngeal swab or tracheal aspirate sample within 14 days of randomization * peripheral capillary oxygen saturation (spo2) ≤ 94% on room air or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation at screening * evidence of infiltrates on chest radiography * females of childbearing age and males, must be willing to practice an effective contraceptive method or remain abstinent during the study period. exclusion criteria: * participation in another clinical trial of anti-viral agent(s) for covid-19 * receipt of any anti-viral agent(s) with possible activity against sars-cov-2 \<24 hours prior to study drug administration \[1\] * mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days * severe multi-organ failure * history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria * known immunoglobulin a (iga) deficiency * females who are pregnant 1. use of remdesivir as treatment for covid-19 is permitted.

Keywords: covid-19 covid coronavirus convalescent plasma
[18f]psma-11 pet/ct phase 3 clinical study

Conditions: Prostate Cancer

Summary: prostate cancer (pca) is the most frequently occurring male cancer in belgium. after treatment with surgery and/or radiotherapy, almost half of the patients suffer from a tumor recurrence, often diagnosed by an increase in serum tumor marker prostate specific antigen (psa) within the first few years after primary treatment. however, for salvage therapy to be successful, precise localization of metastases is necessary to determine the most appropriate treatment. in so-called oligo-metastatic disease targeted therapy may still be curative and prevent the disease from spreading to distant locations. therefore it is of paramount importance to have an accurate tool of medical imaging to localize all possible locations to be treated. recently, prostate specific membrane antigen (psma) has gained interest for pca-specific imaging. due to overexpression of psma in both primary and metastatic pca, radiotracers targeting this protein have shown an increased selectivity and sensitivity compared to conventional imaging. the main objective of this phase 3 trial is to determine the position of \[18f\]psma-11 pet/ct within the field of available radiotracers for diagnosis of prostate cancer. for this, the diagnostic performances of \[18f\]psma-11 will be compared to those of the current state-of-the-art radiotracer \[68ga\]psma-11.


Eligibility criteria:
inclusion criteria: * patients diagnosed with prostate cancer, either in the setting of diagnosis of biochemical recurrence after previous treatment, or at primary diagnosis and staging. exclusion criteria: * age \< 18 years * physically or mentally unfit to perform the sequential procedures * refusal of patient to be informed about accidental findings on scans * history of anaphylactic shock after administration of visipaque ct contrast * serum creatinine concentration \> 2.0 mg/dl and/or estimated glomerular filtration rate \< 60 ml/min.

Keywords: prostate cancer biochemical recurrence 18f-psma pet imaging